MBL77 - AN OVERVIEW

Besides ibrutinib, sufferers with M-CLL, devoid of TP53 aberrations and match adequate to tolerate FCR therapy, should still be superior candidates to the latter, with the profit being this procedure might be done in six months whilst ibrutinib has to be taken indefinitely. This feature could be particularly worthwhile for non-compliant patients or